tiprankstipranks
Trending News
More News >
CSL Limited (AU:CSL)
:CSL
Advertisement

CSL (CSL) AI Stock Analysis

Compare
622 Followers

Top Page

AU:CSL

CSL

(OTC:CSL)

Rating:70Neutral
Price Target:
AU$275.00
▲(27.81% Upside)
CSL's strong financial performance and positive earnings call sentiment highlight its robust position in the biotechnology sector. However, valuation concerns and technical indicators suggest cautious optimism due to market pricing and potential volatility.

CSL (CSL) vs. iShares MSCI Australia ETF (EWA)

CSL Business Overview & Revenue Model

Company DescriptionCSL Limited is a global biotechnology company that researches, develops, manufactures, and markets innovative biotherapies and influenza vaccines. Focused on addressing serious diseases and conditions, CSL operates through two main segments: CSL Behring and Seqirus. CSL Behring is a leader in the plasma protein biotherapeutics industry, providing lifesaving medicines for patients with rare and serious diseases. Seqirus is a major provider of influenza vaccines, leveraging advanced technologies to deliver vaccines to people worldwide. The company is committed to improving patient quality of life and advancing public health.
How the Company Makes MoneyCSL makes money primarily through the development, manufacturing, and sale of biotherapies and vaccines. CSL Behring, the company's largest segment, generates revenue from the sale of plasma-derived therapies and recombinant therapies, which are used to treat conditions such as hemophilia, primary immune deficiencies, and hereditary angioedema. Seqirus contributes to CSL's revenue by producing and selling influenza vaccines to healthcare providers globally. Key revenue streams stem from ongoing innovation, a diverse product portfolio, strategic acquisitions, and long-term partnerships with healthcare providers and governments to secure supply agreements. Additionally, CSL invests in research and development to continuously enhance its product offerings and maintain its position in the biotechnology industry.

CSL Earnings Call Summary

Earnings Call Date:Aug 18, 2025
(Q4-2025)
|
% Change Since: -20.70%|
Next Earnings Date:Feb 18, 2026
Earnings Call Sentiment Neutral
CSL demonstrated strong financial growth and strategic initiatives, including successful product launches and plans to streamline operations and enhance R&D efficiency. However, challenges remain in the form of U.S. policy impacts, competitive pressures in the iron market, and a soft performance in the Seqirus segment.
Q4-2025 Updates
Positive Updates
Revenue and Profit Growth
CSL Group revenue grew by 5% on a constant currency basis, NPATA increased by 14%, and NPAT grew by 17%. Free cash flow increased by 58%, and the final dividend increased by 12% to USD 1.62 per share.
Successful Product Launches
The new ANDEMBRY product for HAE was approved and launched in the U.S., offering once-monthly dosing with a prefilled auto-injector. Positive uptake noted in Germany and Japan.
Strong Hemophilia Franchise Performance
CSL's hemophilia franchise demonstrated 13% growth at constant currency, with IDELVION achieving 10% growth and ongoing positive uptake of HEMGENIX.
R&D and Pipeline Enhancements
Strategic initiatives aim to enhance CSL's R&D efficiency, targeting over USD 0.5 billion in savings by the end of fiscal year 2028, with plans to reinvest in high-priority opportunities.
Positive Strategic Moves
The company announced a multiyear share buyback program and plans to demerge CSL Seqirus as an independent ASX-listed entity, aiming to create strategic benefits and focus for both entities.
Negative Updates
Challenges in U.S. Market
The second half of the year was impacted by the implementation of the IRA Part D reform. Tender losses in the U.S. also affected performance.
Seqirus Revenue Growth Challenges
Seqirus revenue grew only 2%, with the U.S. market showing softness in seasonal influenza vaccine demand.
Iron Market Competition
Generic competition in the EU affected Ferinject's growth, leading to a softer performance in the second half of the fiscal year.
Uncertain Global Policies
Potential impacts from U.S. pharmaceutical sector tariffs and Most Favored Nation pricing remain uncertain, posing a risk to future performance.
Company Guidance
During CSL Limited's Full Year Results Call for Fiscal Year 2025, CEO Paul McKenzie announced several key metrics and strategic initiatives. The company achieved a 5% growth in group revenue on a constant currency basis, with NPATA and NPAT increasing by 14% and 17%, respectively. Leverage improved to 1.8x net debt-to-EBITDA, and free cash flow surged by 58%. Additionally, the final dividend was raised by 12% to USD 1.62 per share. CSL plans to target over USD 0.5 billion in savings by the end of fiscal year 2028, with a focus on reducing costs and simplifying decision-making. A significant move includes the intent to demerge CSL Seqirus as an independent ASX-listed entity in fiscal year 2026, aimed at enabling each entity to focus on core capabilities and distinct growth strategies. The company also announced the reintroduction of a multiyear share buyback program starting this financial year.

CSL Financial Statement Overview

Summary
CSL exhibits consistent revenue growth and robust profitability with a stable balance sheet. However, rising debt levels and volatile cash flow present risks that need monitoring.
Income Statement
75
Positive
CSL has demonstrated consistent revenue growth over the years, highlighted by a strong revenue increase from 2020 to 2023. Gross profit margins have remained robust, reflecting effective cost management. However, the EBIT margin has shown some volatility, indicating fluctuations in operational efficiency. The net profit margin is healthy, but has slightly decreased in the most recent period, suggesting increased expenses or cost pressures.
Balance Sheet
70
Positive
The balance sheet shows a strong equity position, with a growing stockholders' equity over the years. The debt-to-equity ratio is relatively moderate, suggesting a balanced capital structure. However, the total debt has increased significantly, which could pose potential risk if not managed properly. The equity ratio remains stable, indicating financial stability, but the rising debt warrants careful monitoring.
Cash Flow
65
Positive
CSL has maintained positive free cash flow, reflecting the company's ability to generate cash after capital expenditures. However, the free cash flow growth rate has been inconsistent, with notable fluctuations. The operating cash flow to net income ratio is healthy, indicating good cash generation relative to profits. The variability in free cash flow suggests potential challenges in managing capital expenditures efficiently.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue14.69B13.17B10.49B10.33B9.41B
Gross Profit7.56B6.71B5.66B5.80B5.28B
EBITDA4.73B3.90B3.46B2.72B2.18B
Net Income2.64B2.19B2.25B2.39B2.17B
Balance Sheet
Total Assets38.02B54.43B41.22B18.16B15.46B
Cash, Cash Equivalents and Short-Term Investments1.66B2.33B15.18B1.81B1.19B
Total Debt12.18B18.37B14.04B5.81B5.99B
Total Liabilities18.62B27.65B20.02B9.74B8.94B
Stockholders Equity17.33B23.72B21.20B8.38B6.53B
Cash Flow
Free Cash Flow1.51B1.35B1.90B1.97B1.16B
Operating Cash Flow2.81B3.87B3.62B3.65B2.57B
Investing Cash Flow-1.26B-17.61B-2.26B-1.68B-1.41B
Financing Cash Flow-1.28B677.92M10.58B-1.41B-664.30M

CSL Technical Analysis

Technical Analysis Sentiment
Negative
Last Price215.16
Price Trends
50DMA
250.24
Negative
100DMA
247.05
Negative
200DMA
257.94
Negative
Market Momentum
MACD
-10.11
Positive
RSI
25.77
Positive
STOCH
11.83
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CSL, the sentiment is Negative. The current price of 215.16 is below the 20-day moving average (MA) of 253.20, below the 50-day MA of 250.24, and below the 200-day MA of 257.94, indicating a bearish trend. The MACD of -10.11 indicates Positive momentum. The RSI at 25.77 is Positive, neither overbought nor oversold. The STOCH value of 11.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CSL.

CSL Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Neutral
AU$104.18B22.6016.36%1.97%6.07%13.75%
51
Neutral
$7.83B-0.15-40.10%2.29%21.46%-2.01%
$446.17M15.0819.93%0.38%
$2.04B-21.31%
$1.46B14.9351.39%
$238.43M-31.16%
$4.16B335.843.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:CSL
CSL
215.71
-87.56
-28.87%
CLVLF
Clinuvel Pharmaceuticals
7.70
-1.70
-18.09%
MEOBF
Mesoblast Limited
1.54
0.88
133.33%
NURPF
Neuren Pharmaceuticals Limited
10.97
0.77
7.55%
PRRUF
Immutep Ltd
0.19
-0.07
-26.92%
TLPPF
Telix Pharmaceuticals
12.04
-0.88
-6.81%

CSL Corporate Events

CSL Limited Announces Cessation of Securities
Jul 7, 2025

CSL Limited announced the cessation of 7,194 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact CSL’s issued capital structure and reflects the company’s ongoing adjustments to its financial and operational strategies.

The most recent analyst rating on (AU:CSL) stock is a Buy with a A$325.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.

CSL’s ANDEMBRY® Gains FDA Approval for Hereditary Angioedema Treatment
Jun 16, 2025

CSL has announced the FDA approval of ANDEMBRY®, a groundbreaking treatment for hereditary angioedema (HAE), marking its immediate launch in the United States. This approval enhances CSL’s market positioning, offering the first and only prophylactic treatment targeting factor XIIa for HAE, with significant efficacy demonstrated in clinical trials. The treatment’s approval in multiple regions, including the EU and Japan, underscores its global impact and potential benefits for patients, stakeholders, and the company’s operations.

The most recent analyst rating on (AU:CSL) stock is a Buy with a A$325.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.

CSL Limited Appoints Cameron Price as Non-executive Director
Jun 10, 2025

CSL Limited has announced the appointment of Mr. Cameron Price as an independent Non-executive Director, effective October 1, 2025. Mr. Price brings extensive experience from his previous role as General Counsel & Chief Risk Officer at Australia’s Future Fund and his background in mergers & acquisitions and corporate governance. His appointment is expected to enhance CSL’s board with his insights and commercial acumen, potentially strengthening the company’s strategic positioning in global investment markets.

The most recent analyst rating on (AU:CSL) stock is a Buy with a A$310.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.

CSL Limited Announces Cessation of Securities
Jun 4, 2025

CSL Limited announced the cessation of 8,790 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This cessation reflects a specific adjustment in the company’s issued capital, potentially impacting shareholder value and market perception of the company’s securities management.

The most recent analyst rating on (AU:CSL) stock is a Buy with a A$310.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.

CSL Limited Announces Cessation of Securities
May 8, 2025

CSL Limited announced the cessation of 12,039 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This development may impact the company’s capital structure and could have implications for stakeholders regarding the company’s strategic financial management.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 16, 2025